Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methsuximide
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
Details : Methsuximide elevates the seizure threshold and reduces the frequency of attacks through depression of nerve transmission in the cortex.
Brand Name : Celontin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2023
Lead Product(s) : Methsuximide
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?